Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in New-onset Acute Heart Failure
NCT05556044Phase 3
Key facts
- Status
- Recruiting
- Start
- Sep 2022
- Primary completion
- Feb 2024
- Countries
- 1
- Sponsor
- The Chinese University of Hong Kong
- Modality
- Small Molecules
- Drugs
- empagliflozin
- Conditions
- acute heart failure (AHF)
01
Overview
Phase 3, open-label, single-arm trial of empagliflozin in acute heart failure (AHF), sponsored by The Chinese University of Hong Kong. Primary endpoints: Heart failure events at 90 days and All-cause mortality at 90 days. Started Sep 2022; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Empagliflozin 10 MG
Empagliflozin 10 MG daily
03
Endpoints
Primary
Heart failure events
All-cause mortality
Secondary
Kansas City Cardiomyopathy Questionnaire - Total Symptom Score
N-terminal pro-B-type natriuretic peptide
New York Heart Association class
Major Adverse Cardiovascular Event
Occurrence of kidney damage
Weight loss
Quality-adjusted life years gained
6 minute hall walk
Beyond the preview
Go deeper on NCT05556044.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05556044.